Multiple Sclerosis (MS)

Neurology·MeSH: Multiple Sclerosis

Prevalence

120.0 / 100K

Incidence

7.0 / 100K/yr

25 drugs in development·20 companies·5 clinical trials

Drug Pipeline by Phase

Approved(15)

Drug	Company
Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)
dimethyl	Mylan II B.V. (MYL)
fingolimod	ICON plc (ICLR)
fingolimod	Mylan II B.V. (MYL)
fingolimod	SUNSET ISLAND GROUP (SUN)
fingolimod	Teva Pharmaceutical Industries Limited (TEVA)
fingolimod	GT Biopharma, Inc. (GTBP)
fingolimod	DR REDDYS LABORATORIES LTD (RDY)
fingolimod	aTYR PHARMA INC (ATYR)
fingolimod	Aptinyx Inc. (APTX)
plegridy	BIOGEN INC. (BIIB)
Purified Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)
tascenso odt	BICYCLE THERAPEUTICS PLC (BCYC)
teriflunomide	Aptinyx Inc. (APTX)
teriflunomide	Mersana Therapeutics, Inc. (MRSN)

Phase 3(3)

Phase 1(1)

Drug	Company
prn2246/sar442168	Principia Biopharma Inc. (PRNB)

Preclinical(4)

Drug	Company
apitox	Apimeds Pharmaceuticals US, Inc. (APUS)
labp-66	Landos Biopharma, Inc. (LABP)
rpi-78m	NUTRA PHARMA CORP (NPHC)
stat-203	Statera Biopharma, Inc. (CBLI)

Unknown(1)

Drug	Company
Novel MS therapeutic target (discovery)	Adaptive Biotechnologies Corp (ADPT)

Phase 4(1)

Drug	Company
fingolimod	Novartis AG (NVS)

BioSniper tracks 25 drugs in development for Multiple Sclerosis (MS) across 20 companies.

There are 5 clinical trials targeting Multiple Sclerosis (MS) tracked by BioSniper.

The estimated prevalence of Multiple Sclerosis (MS) is approximately 120.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.